In April 2019, MAPS raised $90,190 in new donations and pledges from 796 generous supporters. Of that amount, $47,829 was for general support, $41,901 for MDMA/PTSD Phase 3, and $460 for other MAPS programs.
Currently, MAPS seeks $9 million for European Medicines Agency (EMA)-regulated trials to supplement the data gathered for the FDA, with $897,795 already raised and roughly $8.1 million still to go. We have completed key negotiations with EMA, and we will have a more precise estimate of timetables and costs for Phase 3 EMA trials in mid-2019 after completion of our negotiations with each country in the EMA in which we will have a Phase 3 site, and with each site.
We extend a special thanks to those who so generously supported MAPS last month:
- Young Presidents’ Organization ($10,039)
- Yeonmi Park ($5,000)
- Jiri Techet ($3,000)
- Malkenson Foundation Inc. ($2,500)
- Ronald A. Mis ($1,290)
- Sonny Astani ($1,000)
- Ezekiel Golan $1,000)
MDMA/PTSD Phase 3 Research:
- KJC Intl. Research S.R.L. ($40,000)
MAPS fiscally sponsors like-minded organizations and projects. This list includes donors who have contributed to organizations we fiscally sponsor.
- Cody Swift, RiverStyx Foundation ($34,000 – ICEERS)
- Nicole Panter Dailey ($5,555 – Prescription X)
- Jarrod Stanley ($2,500 – Chacruna)
- Todd Bureau ($1,000 – Prescription X)
- Dr. Sabrina Kay Charitable Foundation ($1,000 – Prescription X)
MAPS relies on the generosity of individual donors to achieve its mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate